Overhead view of a doctor looking at his clipboard

Pipeline

Aldeyra is dedicated to improving the lives of patients suffering from immune-mediated ocular and systemic diseases. We are advancing a broad pipeline of product candidates diversified by chemical composition, mechanism of action, and clinical indication. 

Our clinical pipeline encompasses three distinct biological mechanisms of action: Reactive Aldehyde Species (RASP) inhibition, Dihydrofolate Reductase (DHFR) inhibition, and Chaperome (CHP) inhibition. The immunological activity of our product candidates may potentially lead to diminished levels of pathological inflammation via the down-regulation of immune cell activation or proliferation.

Ocular Diseases

CompoundMechanismPreclinicalPhase 1Phase 2Phase 3Registration

Ocular Disease

Reproxalap

Disease Area: Dry Eye Disease

Mechanism: RASP

RASP
Preclinical
Phase 1
Phase 2
Phase 3
Registration

Reproxalap

Disease Area: Allergic Conjunctivitis

Mechanism: RASP

RASP
Preclinical
Phase 1
Phase 2
Phase 3
Registration

ADX-2191

FDA Fast Track Designation

Disease Area: Proliferative Vitreoretinopathy

Mechanism: DHFR

DHFR
Preclinical
Phase 1
Phase 2
Phase 3
Registration

ADX-2191

Disease Area: Intraocular Lymphoma

Mechanism: DHFR

DHFR
Preclinical
Phase 1
Phase 2
Phase 3
Registration

ADX-103/10X

Disease Area: Retinal Disease

Mechanism: RASP

RASP
Preclinical
Phase 1
Phase 2
Phase 3
Registration

Undisclosed

Disease Area: Ocular Inflammatory Diseases

Mechanism: RASP

Research Collaboration: Undisclosed

RASP
Preclinical
Research Collaboration: Undisclosed
Phase 1
Phase 2
Phase 3
Registration

Systemic Diseases

CompoundMechanismPreclinicalPhase 1Phase 2Phase 3Registration

Systemic Diseases

ADX-1612

Disease Area: Ovarian Cancer

Mechanism: CHP

Research Collaboration: Investigator-Sponsored Trial

CHP
Preclinical
Research Collaboration: Investigator-Sponsored Trial
Phase 1
Phase 2
Phase 3
Registration

ADX-629

Disease Area: Autoimmune Disease (Psoriasis)

Mechanism: RASP

RASP
Preclinical
Phase 1
Phase 2
Phase 3
Registration

ADX-629

Disease Area: Cytokine Release Syndrome (COVID-19)

Mechanism: RASP

RASP
Preclinical
Phase 1
Phase 2
Phase 3
Registration

ADX-629

Disease Area: Allergy (Atopic Asthma)

Mechanism: RASP

RASP
Preclinical
Phase 1
Phase 2
Phase 3
Registration